Screening for biotinidase deficiency in children with unexplained neurologic or developmental abnormalities

Area of Science:

• Biochemistry
• Genetics
• Pediatric Neurology

Background:

• Biotinidase deficiency is an inherited metabolic disorder affecting biotin metabolism.
• Early diagnosis and treatment are crucial to prevent severe neurologic sequelae.
• The prevalence in children with unexplained neurologic conditions is not well-established.

Purpose of the Study:

• To determine if biotinidase deficiency is more common in children with unexplained developmental delay or neurologic abnormalities compared to the general population.
• To assess the diagnostic yield of biotinidase testing in this specific pediatric cohort.

Main Methods:

• A retrospective study of 274 children (aged 2 weeks to 17 years) with unexplained neurologic abnormalities was conducted over four years.
• Clinical data, including IQ/DQ scores, seizures, hearing loss, motor delay, and muscle tone, were collected.
• Patients were screened for biotinidase activity, excluding those with classical deficiency diagnosed during the study.

Main Results:

• None of the 274 children studied, who presented with non-classic findings, had biotinidase deficiency.
• One patient with a classical presentation was diagnosed but excluded from the study cohort.
• The study found no significant association between biotinidase deficiency and unexplained neurologic abnormalities in the studied group.

Conclusions:

• Biotinidase deficiency does not appear to be a common cause of unexplained developmental delay or neurologic abnormalities in children.
• Routine screening for biotinidase deficiency may not be warranted in all children with non-specific neurologic symptoms.
• Targeted biotinidase testing remains essential for children exhibiting clinical features suggestive of the disorder.